옵션 체인은 다양한 행사가격과 만기일에 대한 Ingevity의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Ingevity에 대한 시장 심리를 평가합니다..

Ingevity (NYSE:NGVT) 주식, 옵션 체인

Ingevity

Ingevity Corp is a chemical manufacturer based in the United States. It conducts its operations through three segments, namely Performance Chemicals, Advanced Polymer Technologies, and Performance Materials. The bulk of its revenue is generated by the Performance Chemicals segment which deals with the manufacture and sale of specialty chemicals that find their use in a range of processes such as asphalt paving, oil exploration and production, agrochemicals, adhesives, lubricants, and publication inks. The Performance Materials segment, on the other hand, focuses on automotive carbon products used in automobiles. The Advanced Polymer Technologies segment produces caprolactone and caprolactone-based specialty polymers. The Company generates the majority of its revenue from North America.

benzinga_deal_dispatch2

News

ABBV

BIIB

LNTH

NGVT

NPSCY

RVNC

SAGE

SANW

SLRX

TMUS

대통령 조 바이든은 백악관에서의 마지막 며칠 동안 비폭력 마약 범죄자 석방를 우선시했지만, 틱톡? 이제는 대통령 당선자 도널드 트럼프의 문제이다. AP 통신에 따르면, 바이든은 금지 조치를 시행할 의사가 없으며, 이는 그의 마지막 정식 근무일인 1월 19일에 발효되고 트럼프의 취임식 하루 전이다.

딜 디스패치: 바이든이 틱톡 금지를 트럼프에게 넘기고, 또 다른 유명 소매업체 파산

Ingevity Corp

Editor&#8217;s note: This story was corrected to update the earnings estimates.
Asana, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASAN#NYSE">ASAN</a>) released its first-quarter results after Tuesday's closing bell. Here's a look at the <a href="https://www.benzinga.com/pressreleases/25/06/b45757637/asana-announces-first-quarter-fiscal-2026-results">details from the report.&nbsp;</a>
The Details: Asana reported quarterly earnings of five cents per share, which beat the Street estimate of two cents. Quarterly revenue of $187.27 million exceeded the consensus estimate of $185.4 million.
Read Next: <a href="https://www.benzinga.com/news/space/25/06/45724938/space-stocks-weekly-countdown-rocketlab-gets-analyst-love-while-virgin-galactic-slides-into-june?utm_source=articleShare">Space Stocks Weekly Countdown: RocketLab Gets Analyst Love While Virgin Galactic Slides Into June</a>
For the first quarter of fiscal 2026, Asana reported: 
<ul class="wp-block-list">
<li>The number of Core customers, or customers spending $5,000 or more on an annualized basis, grew to 24,297, an increase of 10% year-over-year. Revenues from Core customers grew 10% year-over-year.</li>
<li>The number of customers spending $100,000 or more on an annualized basis grew to 728, an increase of 20%.</li>
<li>Overall dollar-based net retention rate was 95%.</li>
</ul>
&#8220;Just months after launching AI Studio, we&#8217;ve already crossed $1 million in ARR and head into Q2 with a robust, rapidly growing global pipeline,&#8221; said Dustin Moskovitz, CEO of Asana. 
&#8220;With new offerings like the AI Studio Plus package, and Smart Workflow Gallery, we&#8217;re making these transformative AI capabilities even more accessible,&#8221; Moskovitz added. 
Outlook:&nbsp;Asana sees second-quarter adjusted earnings of four cents to five cents per share, versus the four cent estimate, and revenue in a range of $192 million to $194 million, versus the&nbsp;$192.19 million&nbsp;analyst estimate.
Asana raised its fiscal 2026 adjusted EPS guidance from a range of 19 cents to 20 cents to 22 cents, versus the 33 cent estimate, and widened its revenue outlook from a range of $782 million to $790 million&nbsp;to&nbsp;a new range of $775 million to $790 million, versus the&nbsp;$857.76 million&nbsp;estimate.
ASAN Price Action: According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Asana stock was down 12% at $16.69 in Wednesday's premarket trading. 
Read Next:&nbsp;
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/social-media/25/06/45749596/the-viral-student-loan-solution-people-cant-stop-talking-about?utm_source=articleShare">The Viral Student Loan Solution People Can&#8217;t Stop Talking About</a></li>
</ul>
Photo: Shutterstock

Earnings

After-Hours Center

Movers

Tech

ASAN

Asana Reports Q1 Earnings: Earnings, Revenues Beat (CORRECTED)

Citigroup analyst Marta Romero reinstates Banco Santander (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAN#NYSE">SAN</a>) with a Buy.

Initiation

Analyst Ratings

Citigroup Reinstates Buy on Banco Santander

Elon Musk said on the campaign trail that he would <a href="https://www.benzinga.com/startups/25/01/43391017/2-trillion-by-2026-elon-musks-ambitious-push-to-reinvent-government-spending-with-silicon-valley-powerhouses">slash $2 trillion from the federal budget</a>. Then it became $1 trillion. Then $150 billion. According to Steve Bannon, it&#8217;s now effectively nothing. "None of this makes sense," Bannon said during the <a href="https://www.youtube.com/watch?v=dHI2Vn0hPa0">Semafor World Economy Summit</a> in April, criticizing Musk's Department of Government Efficiency project for falling far short of its ambitious promises.
<h2 class="wp-block-heading">Bannon Doubts Real Savings</h2>
Bannon, a former chief strategist to President Donald Trump, said that although Musk arrived in Washington, D.C. with a bold plan, the results were minimal. "He went from $2 trillion a year to $1 trillion a year to $150 billion next year with nothing this year," Bannon said. &#8220;We need to know exactly what he found as far as fraud goes.&#8221;
Don't Miss:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/money/this-ai-imaging-technology-has-been-used-in-more-than-500-surgeries-now-you-can-be-part-of-the-ai-imaging-revolution">Be part of the next med-tech breakthrough for only $350 — 500+ surgeries already done with nView's AI system.</a></li>
<li>Invest where it hurts — and help millions heal:<a href="https://www.benzinga.com/money/a-cure-for-osteoarthritis-powered-by-everyday-investors-cytonics-is-looking-to-beat-big-pharma-and-disrupt-a-390-billion-market"> Invest in Cytonics and help disrupt a $390B Big Pharma stronghold</a>.</li>
</ul>
Bannon demanded &#8220;specific accounting&#8221; of the DOGE program's work, suggesting that despite Musk's intentions, the effort to cut waste and fraud has lacked real substance. "Treasury's got to sign off, [the Office of Management and Budget] has got to sign off. Every department head. We have to have a letter of certification that not one data set or piece of data&#8230; are held by anyone except the Trump administration and the U.S. Government," he said.
When asked whether he trusts Musk not to misuse government data, Bannon replied: "Trust but verify."
Musk has officially stepped down from DOGE, concluding a 130-day tenure as a "special government employee." In a <a href="https://x.com/elonmusk/status/1927877957852266518">post</a> on his social media platform X on Thursday, Musk expressed gratitude to Trump for the opportunity to reduce wasteful government spending, saying, &#8220;The @DOGE mission will only strengthen over time as it becomes a way of life throughout the government.&#8221;
Trending: Maximize saving for your retirement and cut down on taxes: <a href="https://www.benzinga.com/money/wideradvisor-retirement-planning">Schedule your free call with a financial advisor to start your financial journey – no cost, no obligation</a>.
<h2 class="wp-block-heading">Numbers Don't Add Up</h2>
<a href="https://www.theatlantic.com/politics/archive/2025/05/musk-doge-spending-cuts/682736/">The Atlantic</a> reported that DOGE's actual verified budget savings totaled just $2 billion, a far cry from the $165 billion the agency claimed at the time of its analysis in early May. According to the report, the project has been plagued by <a href="https://www.benzinga.com/government/regulations/25/05/45466451/elizabeth-warren-torches-doges-social-security-fraud-claims-pointing-at-internal-memo-discovery-says-elon-musk-jd-vance-and-trump-are-lying">false savings</a>, repeated counting of the same cuts, and expired contracts being listed as fresh reductions. Musk&#8217;s team once <a href="https://www.benzinga.com/news/25/03/44065790/elon-musks-government-overhaul-faces-revolt-even-from-trumps-own-officials">claimed $8 billion in savings</a> from ending an $8 million contract.
&#8220;If you thought DOGE was really about cutting costs, you weren't in on the joke,&#8221; The Atlantic concluded.
Even Musk himself has admitted it didn't go as planned. In an interview with the <a href="https://www.washingtonpost.com/business/2025/05/27/elon-musk-spacex-starship-doge/">Washington Post</a> recently, he said, "The federal bureaucracy situation is much worse than I realized." He acknowledged DOGE had become a political scapegoat: "DOGE is just becoming the whipping boy for everything."
See Also: <a href="https://www.benzinga.com/money/are-you-rich">Are you rich?</a> Here&#8217;s what Americans think you need to be considered wealthy.
Frustration On All Sides
Musk also expressed disappointment with Trump's signature spending package, the so-called "Big Beautiful Bill," telling <a href="https://www.youtube.com/watch?v=fLbx2PJ4pqE">CBS News</a>: "I was disappointed to see the massive spending bill, frankly, which increases the budget deficit, not just decreases it, and undermines the work that the DOGE team is doing."
For Bannon, the project's failure underscores the need for structural reform and transparency. He insisted the country is running out of time to fix its finances. "Our choices narrow every day," he said. "The current system is not sustainable."
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/money/gbr-savings-by-age">If You're Age 35, 50, or 60: Here&#8217;s How Much You Should Have Saved Vs. Invested By Now</a></li>
<li>Can you guess how many retire with a $5,000,000 nest egg? <a href="https://www.benzinga.com/money/5mil-nest-egg-adv">The percentage may shock you</a>.</li>
</ul>
Image: Shutterstock

Steve Bannon Says Elon Musk's DOGE Cuts Went From $2 Trillion To $150 BilSteve Bannon Says Elon Musk's DOGE Cuts Went From $2 Trillion To $150 Billion And Now Nothing—'None Of This Makes Sense'

Guggenheim analyst Ali Faghri downgrades Aptiv (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APTV#NYSE">APTV</a>) from Buy to Neutral.

Downgrades

APTV

Guggenheim Downgrades Aptiv to Neutral

<a href="https://truthsocial.com/@realDonaldTrump/posts/114625064616541014" title="https://truthsocial.com/@realDonaldTrump/posts/114625064616541014">https://truthsocial.com/@realDonaldTrump/posts/114625064616541014</a>

Macro Economic Events

Economics

Federal Reserve

Donald Trump Posts On Truth Social "ADP NUMBER OUT!!! "Too Late" Powell must now LOWER THE RATE. He is unbelievable!!! Europe has lowered NINE TIMES!"

Sagimet Biosciences Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMT#NASDAQ">SGMT</a>) said on Wednesday that denifanstat met all primary and secondary endpoints in a Phase 3 trial for moderate to <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">severe acne vulgaris</a>.
The trial was conducted by Sagimet&#8217;s license partner, Ascletis Bioscience Co. Ltd., <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/g45765051/sagimet-biosciences-announces-positive-phase-3-results-for-denifanstat-for-the-treatment-of-modera" rel="noreferrer noopener">in China</a>.
Denifanstat is a once-daily oral small-molecule fatty acid synthase (FASN) inhibitor being developed by Ascletis as ASC40 for acne in China and by Sagimet for metabolic dysfunction-associated steatohepatitis&nbsp;(MASH) in the rest of the world.
Also Read: <a href="https://www.benzinga.com/news/health-care/25/06/45756147/jazz-pharmas-zepzelca-combo-shows-survival-edge-in-lung-cancer-study">Jazz Pharma&#8217;s Zepzelca Combo Shows Survival Edge In Lung Cancer Study</a>
Additionally, Sagimet recently initiated a Phase 1 first-in-human trial with a second FASN inhibitor, TVB-3567, that is planned to be developed for acne in the U.S.
The trial randomized 480 patients in China to receive either denifanstat once daily or a placebo for 12 weeks.
For the primary endpoint of treatment success, defined as an Investigator&#8217;s Global Assessment score of 0 (clear) or 1 (almost clear) with at least a 2-point decrease from baseline at week 12, the denifanstat group demonstrated a statistically significant 33.2% rate over the placebo group&#8217;s 14.6%.
Additional goals further corroborated denifanstat&#8217;s efficacy versus placebo, including:
<ul class="wp-block-list">
<li>Reduction in total lesion count (57.4% vs 35.4%).</li>
<li>Reduction in inflammatory lesion count (63.5% vs 43.2%).</li>
<li>Reduction in non-inflammatory lesion count (51.9% vs. 28.9%).</li>
</ul>
Ascletis reported that denifanstat was generally well-tolerated. Following 12 weeks of once-daily oral administration at 50 mg, treatment-emergent adverse events (TEAE) incidence rates were comparable between denifanstat and placebo.
All denifanstat-related adverse events (AEs) were mild or moderate. There were no denifanstat-related grade 3 or 4 AEs and no denifanstat-related serious AEs. No deaths were reported.
These Phase 3 results confirm that FASN inhibition represents a potential therapeutic approach within acne. Ascletis has indicated that it plans to submit denifanstat for approval to the China National Medical Products Administration.
Building on Ascletis&#8217; Phase 3 results, Sagimet has recently initiated a Phase 1 first-in-human clinical trial with a second oral FASN inhibitor drug candidate, TVB-3567, that is planned to be developed for acne in the U.S.
In other notable pharmaceutical industry news, GSK plc&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>) agreed to acquire&nbsp;Boston Pharmaceuticals&#8217;&nbsp;lead asset, efimosfermin alfa, a phase 3-ready, investigational specialty medicine for treating and preventing the progression of <a href="https://www.benzinga.com/general/biotech/25/05/45406673/gsk-to-buy-phase-3-ready-liver-disease-drug-for-up-to-2-billion" target="_blank" rel="noreferrer noopener">steatotic liver disease</a> in May.
Under the agreement, GSK will pay up to $2 billion in total cash consideration, including $1.2 billion upfront, with the potential for additional success-based milestone payments totaling $800 million.
This highlights ongoing investment in the liver disease space, an area where Sagimet is also active with its MASH program.
Price Action: SGMT stock is trading higher by 31.7% to $4.78 premarket at last check Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/health-care/25/06/45756266/alto-neuroscience-adds-intriguing-depression-asset-via-over-100-million-deal">Alto Neuroscience Adds &#8216;Intriguing&#8217; Depression Asset Via Over $100 Million Deal</a></li>
</ul>
Image via Shutterstock

Biotech

Health Care

General

SGMT

Sagimet's Partner Achieves Positive Results With Oral Acne Drug In Phase 3 Acne Trial In China, Stock Jumps

HSBC analyst Cenk Orcan upgrades Embraer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ERJ#NYSE">ERJ</a>) from Hold to Buy and raises the price target from $45 to $57.

Upgrades

Price Target

Embraer-Empresa Brasileira De Aeronautica

HSBC Upgrades Embraer to Buy, Raises Price Target to $57

HCW Biologics Inc. ("HCWB" or "HCW Biologics"), (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCWB#NASDAQ">HCWB</a>), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, and WY Biotech Co., Ltd., a China-based company specializing in the early-stage development of recombinant protein drugs and gene/cell therapies, announced today that WY Biotech has completed its due diligence related to HCWB's technology transfer report, including the characterization of the cell line, delivered on May 13, 2025. In addition, WY Biotech confirmed its commitment to proceed with the development and commercialization of the licensed molecule, HCW11-006, for in vivo therapeutic applications. The Agreement is now fully binding and HCW Biologics has earned the $7.0 million upfront license fee under the terms of the Agreement, as amended.
In addition to the $7.0 million upfront payment, HCWB is eligible to receive additional significant development milestone payments and double-digit royalties on future product sales. Furthermore, HCWB will share a substantial portion of the proceeds from a future transaction(s) involving the molecule, if such a transaction occurs. HCWB also has a payment-free, milestone-free, and royalty-free option to recapture the development and commercialization rights of this molecule for the United States, Canada, Central America, and South America (Opt-in Territory) after the conclusion of the Phase 1 clinical trial. WY Biotech is financially responsible for all costs associated with research and development, manufacturing, clinical development, regulatory approval, and commercialization for the molecule. HCWB will be responsible for costs associated with clinical development, regulatory approval, and commercialization in the Opt-in Territory, if HCWB exercises its opt-in rights. Both companies will work cooperatively in the development stage with a global focus for clinical development and partnering.

HCWB

HCW Biologics Secures $7M License Fee As WY Biotech Completes Due Diligence On HCW11-006

Macro Notification

Econ #s

ADP Nonfarm Employment Change For May 37K Vs 111K Est.; 60K Prior

Stephens &amp; Co. analyst Todd Weller maintains CrowdStrike Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) with a Overweight and raises the price target from $450 to $540.

CRWD

Stephens & Co. Maintains Overweight on CrowdStrike Holdings, Raises Price Target to $540

reAlpha Tech Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIRE#NASDAQ">AIRE</a>) ("reAlpha" or the "Company"), an AI-powered real estate technology company, today announced a strategic leadership transition to support its next phase of growth. Effective June 3, 2025, Mike Logozzo, President and Chief Operating Officer, has been appointed Chief Executive Officer, and Giri Devanur, reAlpha's founder, Chairman of the Board and former Chief Executive Officer, has assumed the role of Executive Chairman of the Board. As part of this transition, Mr. Logozzo will serve as Interim Chief Operating Officer until a successor is identified.
Since joining reAlpha, Mr. Logozzo has played a pivotal role in the company's momentum, serving as Chief Financial Officer and later as President and Chief Operating Officer. Under his guidance, reAlpha has expanded its national presence, launched the proprietary AI platform Claire, and enhanced its real estate, mortgage, and title capabilities. His proven success across operations, financial services, and innovation has been critical to reAlpha's ongoing advancement.

Management

AIRE

reAlpha Tech Corp. Appoints President And COO Mike Logozzo As New CEO, As Founder Giri Devanur Transitions To Executive Chairman Role; Logozzo To Also Serve As Interim COO During Leadership Search

Wolfe Research analyst Steve Fleishman maintains Cheche Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCG#NASDAQ">CCG</a>) with a Outperform and raises the price target from $335 to $350.

Wolfe Research Maintains Outperform on Cheche Group, Raises Price Target to $350

<a href="https://www.globenewswire.com/Tracker?data=vzdj-uBtDE9BfwfY4CNUyIvLcwyvR2fgom87L8iB02gZ160yifipO7kHmup1liDRd-B1JPSV-U4AOqhtt9S2tBO0FS35ROxMrh9H8J9CQW8=">Akebia Therapeutics&#xAE;, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKBA#NASDAQ">AKBA</a>), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the <a href="https://www.globenewswire.com/Tracker?data=JGOn-OYYoMVTp8heDhWiIuJKGHfmd48rqGv5eHQQ8kc7gAgrlFsj3_GgtDnF9APh7splsiW8lglZawZzHbn8CtJmJNQ5KHBPx0Iwr-01R86W9aI6wSu-probtX_Q0JQcxNJ1KPwxbyJZJlUjlcb_Imk8p1hYV0r6y6MGDMeckBQ=">Journal of the American Society of Nephrology</a> (JASN) has published pre-specified analyses for the U.S. and non-U.S. patient subgroups from the vadadustat global phase 3 clinical program, which included two trials in patients with dialysis-dependent chronic kidney disease (DD-CKD; INNO2VATE) and two trials in patients with non–dialysis-dependent CKD (NDD-CKD; PRO2TECT).
The vadadustat global phase 3 clinical trials were open-label, randomized, noninferiority trials that compared the safety and efficacy of vadadustat with darbepoetin alfa in adult patients with CKD-related anemia. Data from the pre-specified analyses for the U.S. patient subgroup demonstrate that among patients with DD-CKD, safety and efficacy of vadadustat and darbepoetin alfa in the U.S. and outside the U.S. were similar. Among the U.S. patient subgroup with NDD-CKD, safety and efficacy outcomes were similar, but the risk for major adverse cardiovascular event (MACE) with vadadustat was higher than darbepoetin alfa outside the United States. In these analyses, safety was measured by time to first MACE and efficacy was measured by mean change in hemoglobin. The article titled, "Safety and Efficacy of Vadadustat for the Treatment of CKD-Related Anemia within and outside the United States," is available <a href="https://www.globenewswire.com/Tracker?data=Q8EAVRvCjTfUeHUP9KZPv1XrVAofNmL7y37CuUJMd50apQdt2jSxjTuWAeIzImcKumpGwzv_CTAcPULWd7nBmc_JvEHVLGE99uMinZDXcjPFXAhtpm-tPAT2JysrmOo6498dIj5-E-5dobmq0yM9kBl2QtAIexVYRMZFKsZj-ng=">here</a>.
Vafseo&#xAE; (vadadustat) was approved by the U.S. Food and Drug Administration in March 2024 for the treatment of anemia due to chronic kidney disease in adults who have been receiving dialysis for at least three months. Vafseo has been available in the U.S. since January 2025.

AKBA

Akebia Therapeutics Announces Publication In JASN Of U.S. And Non-U.S. Subgroup Analyses From Vadadustat Global Phase 3 Trials, Showing Comparable Safety And Efficacy In Dialysis-Dependent CKD Patients And Highlighting Elevated MACE Risk In U.S. Non–Dialysis-Dependent CKD Patients

Global

CUPR

Cuprina Holdings Announces Launch Of Saudi-Based Lab To Manufacture MEDIFLY Maggot Therapy For Chronic Wounds In MENA Region And Exclusive Rights To Distribute Medicinal Leeches Across GCC, Advancing Regional Expansion In Biomedical Treatments

Litchfield Hills analyst Theodore O'Neill initiates coverage on Algorhythm Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIME#NASDAQ">RIME</a>) with a Buy rating and announces Price Target of $5.

RIME

Litchfield Hills Initiates Coverage On Algorhythm Holdings with Buy Rating, Announces Price Target of $5

AMOD

Alpha Modus Announces $31M Capital Structure Overhaul as CEO-Affiliated Trusts Convert Series C Preferred Into 26.5M Class A Shares

WIIM

ENSC

Ensysce Biosciences shares are trading higher after the company announced it was awarded the second $5.3 million installment of a $15 million, three-year grant from the National Institute on Drug Abuse.

Fangdd Network Group Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DUO#NASDAQ">DUO</a>) ("FangDD" or the "Company"), a customer-oriented property technology company in China, today announced that its share consolidation ("Share Consolidation"), involving the consolidation of every 16 ordinary shares with a par value of US$0.0005625 per share, into 1 ordinary share with a par value of US$0.009 per share,&nbsp;will take effect at 8:00 a.m. Eastern Time on June 9, 2025. The Company's Class A ordinary shares will open for trading on Nasdaq on June 9, 2025, on a post-split basis, under the existing ticker symbol "DUO," with a new CUSIP number of G33147128.

Stock Split

Fangdd Network Group Announces 1-for-16 Share Consolidation Effective June 9, 2025

Loop Capital analyst Alan Gould initiates coverage on Lionsgate Studios (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LION#NYSE">LION</a>) with a Hold rating and announces Price Target of $8.

LION

Loop Capital Initiates Coverage On Lionsgate Studios with Hold Rating, Announces Price Target of $8

Press Releases

Ingevity elects Kevin Willis to its board of directors

Ingevity announces dates for fourth-quarter and full year 2024 earnings release and webcast

Ingevity announces plans to explore strategic alternatives for Performance Chemicals Industrial Specialties product line and North Charleston CTO refinery; releases preliminary 2024 financial results

Comments

Ingevity

Ingevity (NGVT) 옵션

Ingevity (NYSE:NGVT) 주식, 옵션 체인

뉴스

파트너 / 기고자

벤징가 글로벌